Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors
Conditions
Interventions
Tarlatamab
Temozolomide (TMZ)
Locations
11
France
Institut de Cancérologie de l'Ouest
Angers, France
Hôpital Universitaire d'Angers
Angers, France
CHU de Bordeaux
Bordeaux, France
Hôpital Saint-André
Bordeaux, France
Hôpital Neurologique Pierre Wertheimer
Bron, France
Centre Oscar Lambret
Lille, France
Start Date
November 4, 2025
Primary Completion Date
October 1, 2029
Completion Date
October 1, 2030
Last Updated
April 22, 2026
NCT03206060
NCT05099003
NCT03340506
NCT02800486
NCT06503146
NCT07486713
Lead Sponsor
Centre Leon Berard
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions